Whalesbook
📉 The Financial Deep Dive
Innova Captab Limited has delivered a strong performance in Q3 FY26, demonstrating significant year-on-year growth across key financial metrics. The company reported revenue from operations at ₹450.3 crore, marking a substantial 42.3% increase compared to the same period last year. For the nine-month period ending December 31, 2025 (9M FY26), revenue reached ₹1,182.2 crore, up 27.3% YoY.
The company's strategic focus on its business verticals yielded impressive results. The CDMO (Contract Development and Manufacturing Organization) business generated ₹298.7 crore in Q3 FY26, a 29% YoY jump. The branded generics segment exhibited exceptional momentum, with Q3 FY26 revenue climbing to ₹151.6 crore, a remarkable 79% YoY increase. For the 9-month period, branded generics revenue stood at ₹368.4 crore, growing 56% YoY.
Consolidated EBITDA for Q3 FY26 was ₹71.1 crore, reflecting a 39.6% YoY increase, while EBITDA margins remained steady at 15.8%. For 9M FY26, EBITDA stood at ₹183.7 crore (up 24.8% YoY) with margins at 15.5%. Profit After Tax (PAT) for Q3 FY26 was ₹42.1 crore, and ₹102.8 crore for 9M FY26.
🚀 Strategic Analysis & Impact
The Jammu facility is emerging as a critical growth driver, reporting ₹89 crore in revenue for Q3 FY26, an increase from ₹60 crore in Q2 FY26. Management projects it to be EBITDA breakeven soon and contribute positively from FY27. The company maintained its FY26 revenue guidance for Jammu between ₹270-280 crore. Capacity utilization at its Baddi, Dehradun, and Taloja facilities is between 55-60%, with the Jammu facility in its initial ramp-up phase.
🚩 Risks & Outlook
Management expressed confidence in sustaining momentum, projecting an overall company growth of over 20% YoY for FY27 and onwards. EBITDA margins are expected to stay within the 15-17% range, with potential for improvement as the Jammu facility scales. However, management cautioned that future strategic growth initiatives might exert some pressure on the P&L. API prices, while stable QoQ, remain negative YoY, indicating potential input cost challenges. The long-term target for export vs. domestic revenue is approximately 35-65%.
Key operational achievements include obtaining prestigious GMP certifications for its Baddi unit (UK-MHRA for cephalosporins) and its Jammu blocks (PIC/S via SMDC Ukraine). The Jammu facility is progressing with commercial operations with marquee CDMO partners, validating its capabilities for highly regulated markets. The acquired Sharon business is also performing well.
The company's outlook is focused on leveraging advanced manufacturing capabilities, expanding its product portfolio, and increasing geographical diversification to ensure sustained revenue acceleration and profitability. The ramp-up of the Jammu facility and continued growth in branded generics are pivotal.